Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.
OBESITY RESEARCH SOLUTIONSThe anaphylatoxin C3a induces a range of responses by activating its G protein-coupled receptor, C3aR, resulting in calcium mobilization.1 SB 290157 is a non-peptide antagonist of C3aR, competitively blocking C3a binding with an IC50 value of 200 nM.2 It potently inhibits a wide variety of C3a-induced responses in cells, including calcium increase in human neutrophils (IC50 = 28 nM) and ATP release from guinea pig platelets (IC50 = 30 nM).2 SB 290157 is also effective in vivo, reducing inflammation in a variety of animal models.2,3,4 It also significantly reduces or reverses diet-
WARNING This product is not for human or veterinary use.
1. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. The Journal of Biological Chemisty 271(34), 20231-20234 (1996).
2. Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J. Immunol. 166(10), 6341-6348 (2001).
3. Comparative anti-
4. Effect of the C3a-
5. C5aR and C3aR antagonists each inhibit diet-
6. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood 103(6), 2071-2078 (2004).
7. The C3a receptor antagonist SB 290157 has agonist activity. Immunol. Lett. 100(2), 139-145 (2005).
8. Agonist activity of the small molecule C3aR ligand SB 290157. J. Immunol. 174(12), 7479-7490 (2005).